Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA CAR-T in Relapsed or Refractory Multiple Myeloma
NCT04447573Unknown
- Sponsor
- Senlang Bio
- Start
- Jun 2020
- Primary completion
- Aug 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of BCMA-CAR-T in multiple myeloma (MM), sponsored by Senlang Bio. Primary endpoints: Incidence and severity of adverse events at 1 month and Overall Remission Rate at 3 months. Status: unknown.
02
Drugs
BCMA-CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04447573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447573.